**Enhancing the Efficiency of Animal-Alternative *In Silico* Drug Cardiotoxicity Prediction through CUDA-Based Parallel Processing**

Iga Narendra Pramawijaya1\*, Ariyadi1, Aroli Marcellinus1 , Ali Ikhsanul Qauli1 , Ki Moo Lim1,2

1: Computational Medicine Lab, Department of IT Convergence Engineering, Kumoh National Institute of Technology, Gumi, 39177, Republic of Korea

2: Computational Medicine Lab, Department of Medical IT Convergence Engineering, Kumoh National Institute of Technology, Gumi, 39177, Republic of Korea

\*: [iga@kumoh.ac.kr](mailto:iga@kumoh.ac.kr)

**Abstract**

This research focuses on enhancing in silico cardiotoxicity prediction by utilising Graphics Processing Unit (GPU)-based parallel computing. Traditional Central Processing Unit (CPU)-based simulations are computationally expensive, especially for large-scale studies. By leveraging CUDA programming, this research aims to optimise simulation efficiency while maintaining the accuracy of cellular electrophysiological models. The study employed three well-established cardiac cell models: ORd 2011, ORd 2017, and ToR-ORd. Simulations were conducted using GPU-based implementations of ordinary differential equation (ODE) solvers, with the Rush-Larsen method applied for ORd 2011 and a Forward Euler approach for ORd 2017 and ToR-ORd. The simulations were validated against CPU results, with performance evaluated in both drug-free and drug-induced conditions. GPU simulations demonstrated equivalent accuracy to CPU-based results, replicating action potential dynamics and key biomarkers. However, the Forward Euler solver required more computation time compared to the Rush-Larsen method. Computational performance analysis revealed significant efficiency improvements (up to 49 times in fastest configuration) in GPU-based simulations. This research successfully validates GPU-based parallel computing as a reliable and efficient approach for *in silico* cardiotoxicity prediction. The findings support its potential for accelerating drug discovery processes while reducing reliance on animal testing. Future work will focus on expanding model complexity and variabilities to further enhance the system’s applicability.

**Keywords:** In silico, cardiotoxicity, CUDA, GPU Parallel Programming

**1 Introduction**

(research motivation) Cardiovascular diseases are the leading global causes of death, which emphasizes the importance of effective methods for cardiac drug discovery. Traditionally, drug cardiotoxicity prediction is achieved using animal testing, which takes time due to ethical clearance and effortful. Modern *in silico* or computer-based methods for drug cardiotoxicity prediction show promising results as an animal-alternative solution. Nevertheless, at some point, this approach is computationally inefficient due to large amount of sample it needs to compute to mimic natural variations. As the sample size increases, the complexity of the calculations grows, resulting in longer processing times and reduced efficiency.

This efficiency limitation makes it difficult for traditional computational approaches to handle large-scale simulation (such that uses multi-sample scenario or inter-individual variations) within a reasonable timeframe. This research introduces parallelisation to address current *in silico* drug cardiotoxicity simulations inefficiencies. By implementing NVIDIA’s CUDA (Compute Unified Device Architecture)-based parallel programming on Graphics Processing Units (GPU) [1].

(this research benefits) Parallel computing method can significantly accelerate overall computational process. The parallelisation enables faster handling of large-scale simulations, makes computational time decreased. Time advancement gained through this approach can reduce drug development cost, by accelerating preclinical test and reliance on animal testing.

(cpu parallelisation) Parallelisation has been a valuable concept in computational biology. Previous approaches tried to parallelise Central Processing Units (CPU)-based *in silico* simulation by using OpenMP [2], MPI [3], and such. These approaches directly manage multiple CPU to run simultaneously, simulating different drug samples. These approaches find major bottleneck when simulating thousands of drug samples become the norm. One of common CPU parallel computing uses 10 CPUs, means it can only handle 10 drug samples in the same time.

(adding berghoff and their result) Other than biological cell, Cells in Silico (CiS) framework developed by Berghoff et al. [8] provides a modular and parallel design for simulating biological tissue growth and development. This flexibility allows researchers to configure various model assumptions for diverse research questions. A key application of CiS was the simulation of a 1000³ voxel-sized cancerous tissue at sub-cellular resolution, showcasing its ability to handle complex biological processes with high detail.

(adding other GPU simulations and their result) The use of GPUs in biological cell computing has also been explored extensively in prior researches. Martinez et al. [9] introduced an adaptive parallel simulator to mitigate performance loss in massive parallel membrane computing devices, also known as P systems. By extending an existing simulator for Population Dynamics P systems, their approach improved performance by up to 2.5 times on both GPUs and multicore processors. Similarly, McIntosh-Smith et al. developed BUDE (Bristol University Docking Engine), a drug discovery tool for molecular docking, to work with OpenCL, a standard for parallel programming. Their adaptation enabled peak performance of 46%, or 1.43 TFLOP/s, on a single Nvidia GTX 680 [10]. Amar et al. extended parallelisation to biochemical simulations of metabolic pathways, while Barth et al. leveraged parallel computing in BUDE to handle more complex models with an increased number of chemicals and reactions, achieving more realistic and computationally efficient outcomes [11].

(adding in silico contribution to treat cardiac conditions) Recent work has increasingly focused on using *in silico* methods to address specific cardiac conditions and evaluate pharmacological interventions. For example, Whittaker et al. employed computational modelling to examine mutations linked to Short QT Syndrome and their effects on atrial arrhythmias. Their study demonstrated how in silico simulations could assess drug responses and inform strategies for treating genetic cardiac disorders [12].

(Research gap in cardiotoxicity prediction) Advances in computer hardware and parallel processing have further enhanced the speed and efficiency of *in silico* cardiac simulations, enabling the analysis of larger datasets and more intricate models. However, despite these advancements, optimising *in silico* simulations specifically for cardiotoxicity prediction remains underexplored. Therefore, this study main goal is to improve the efficiency and scalability of cardiotoxicity simulations by employing CUDA-based parallel processing techniques. The research aims to:

1. Address computational bottlenecks caused by increasing sample sizes and complex calculations in traditional methods.
2. Optimize GPU resources for faster, large-scale simulations without compromising accuracy.
3. Validate the accuracy and reliability of GPU-based simulations compared to CPU-based, both in single-core and multi-core scenario.
4. Develop a practical and cost-effective approach suitable for real-world drug discovery applications, reducing reliance on animal testing.

**2 Methodologies**

(Research steps) This chapter describes the development process of the GPU-based cardiac cell simulation software. The focus is on enabling multi-sample simulations, where each cardiac cell model is simulated in parallel. Additionally, this chapter will briefly explain how ordinary differential equations (ODEs) in the cell models are solved within this framework. The goal is to ensure that researchers or software engineers can follow the steps, to replicate the parallelisation process and build their own GPU-based multi-sample simulation platforms.

(CellML for this research) This research leverages the flexibility provided by the CellML platform, an XML-based language designed to represent and share mathematical models of biological cells [4]. CellML ensures standardisation across models, enabling translation into various programming languages [5]. It also includes models converted from the Systems Biology Markup Language (SBML), enhancing accessibility for researchers [6-7]. This study utilises three cell models: O’Hara-Rudy 2011 [13], O’Hara-Rudy 2017 [14], and ToR-ORd [15], demonstrating the platform's versatility in supporting diverse simulations.



**Fig. 1.** Action Potential from GPU simulation in ORd 2011 model, compared to CPU simulation in non-drug and under-drug situation.

(Modification from standard CellML code) Once cell model file is acquired in C or C++ format, conversion in terms of GPU memory adjustment and offsetting is needed. CUDA-based application heavily depends on how data is transferred between the host in the central processing unit (CPU) and device (GPU), as well as how it is organized within the GPU's memory.

(GPU memory usage in this research) This research uses three types of GPU memory: global, shared, and constant memory. Proper adjustment of these memory types can significantly enhance computational efficiency. In this research, the global memory is used for storing variables, constant memory for orchestrating commands from CPU, and shared memory used to optimise GPU to CPU feedbacks.

(selecting core per block) In this research, selecting an optimal number of threads per block is crucial to maximising utilisation of shared memory. Two factors need to be considered to optimise performance when selecting core per block value: thread grouping in CUDA, and number of samples. CUDA executes threads in groups called warps, which consist of 32 threads [16]. Using a block size that is a multiple of 32 ensures that all warps are fully utilised, minimising idle threads and maximising efficiency. It is known that this configuration is not transferable across different GPUs. As the time writing this, NVIDIA 40xx series GPU supports 32 core per block, while older series like the 30xx only support 16 core per block.

(sample size correlation to core per block) The choice of cores per block was also influenced by the number of samples. Each simulation sample usually comes in the multiplication of 2000 (2000, 4000, etc.). To optimise warp utilisation (with warps consisting of 32 threads), To optimize warp utilization, the number of cores should be close to 32 and evenly divisible by 2000. Through trial and error, 20 cores per block were found to provide the most efficient configuration. This adjustment ensures that each sample is allocated its own computing core. Code in this research is configured to use 32 cores per block. However, if hardware limitations issue raises, the number of cores per block decreased to 20, maintaining parallelisation.

(Offsetting for thread management) Offsetting is a technique used to efficiently manage data indexing, ensuring thread indices map to the correct memory addresses. This reduces memory conflicts and improves performance, particularly when dividing large datasets across multiple threads and blocks. In this research, offsetting was used to simplify multi-dimensional inputs by converting them into 1D arrays. Instead of using a vector of structs as in the CPU version, each sample is identified by a unique `sample\_id`, with rows in the 1D array allocated accordingly. For example, in the `STATES` array with 43 columns, indices 0–42 correspond to `sample\_id = 0`, indices 43–84 to `sample\_id = 1`, and so on. Figure 1 shows offsetting implementation visually. Offsetting approach ensures efficient data access and processing in the GPU-based simulation.

(Method to solve ODEs) The model relies on algebraic calculations and dynamic functions expressed in the form of ordinary differential equations (ODEs), which are essential for simulating the complex behaviours of biological systems. To efficiently solve these ODEs within a CUDA-based parallel processing framework, two distinct numerical methods were employed depending on the specific cell model: the Rush-Larsen method and a custom implementation of the forward Euler method. These methods were chosen to balance computational efficiency, numerical stability, and compatibility with the CUDA architecture. This research implements the ODE solver inside the cell model code as a function.

(Using Rush-Larsen in ORd 2011) For the ORd 2011 model, the Rush-Larsen method was utilised due to its computational efficiency and computational stability in this context. This method effectively integrates stiff components of the equations, making it well-suited for the dynamic features of the ORd 2011 model. This method was implemented with a dynamic time-stepping mechanism by adjusting the time step during each iteration, while balancing acceptable numerical errors [17].

(Implement Rush-Larsen in other cell models) Initially, the Rush-Larsen method was meant to be used across all cell models. However, when applied to ORd 2017 and ToR-ORd models, this approach exhibited instability, failing to provide reliable results. To address this limitation, a simple forward Euler method was implemented for these two models.

(explaining forward euler) Forward Euler is a simple method to solve ODE in particular time. The forward Euler method calculates the next value of a variable by taking its current value (STATES array) and adding the product of the rate (RATES array) of change and the time step, mentioned as *dt*. This straightforward approach makes the method computationally simple and easy to implement. Simply, it is expressed as in Equation 1:

*xn+1=xn + rate(xn) ⋅ Δt* (1)

where *xn+1* is the current value, *rate(xn)* represents the rate of change at *xn*, and *Δt* is the time step. In the converted code, a function should be added to implement this calculation.

(Trade-off in Forward Euler) While the Euler method produced accurate and stable results, especially for the ORd 2017 and ToR-ORd models, it proved to be computationally intensive, significantly increasing the runtime. To optimise the parallelisation process, algorithm was simplified, enables parallel threads to process multiple samples rather than multiple equations simultaneously. Despite the trade-off between computational speed and stability, this combination of methods ensures that the CUDA-based framework effectively supports the diverse requirements of different cell models, while maintaining accuracy and to reduce numerical errors.

(in silico step of simulation) The simulation consists of two different stages, phase to amplify drug effect by running the simulation for multiple times, and phase to record the drug effect by running for just once. Result from the first phase is a cache file, which represents the initial phase before observation. During this phase, the function runs the simulation for thousands of cycles (referred to as paces) to amplify the drug effects within the model.

(post processing step of simulation) After this initial phase, the function to run the second phase is executed, which generates the biomarker file and the time-series data files. This function uses the output from the first phase as input. All output files from the second phase are organised into a dedicated folder within the result directory for efficient storage and retrieval. As a whole, the simulation produces two distinct types of output files, a biomarker file and time-series data files, along with one intermediate cache file.

(explaining output file and its content) The biomarker file provides a summary of key features extracted from the simulation for each sample. It includes data such as sample numbers, qNet, qInward, and action potential shape analysis result. These biomarkers represent crucial physiological parameters simulated under drug influence, and they are instrumental for downstream analyses, such as machine learning-based predictions. The time-series file offers a detailed temporal view of each sample’s behaviour. Each sample has its own individual time-series file; thus, a simulation involving 2000 samples will result in 2000 time-series files. These files capture parameters such as time, action potential, voltage gradient over time, Cai, INa, INaL, ICaL, IKs, IKr, IK1, and Ito. Using this detailed data, it is possible to plot the drug-induced cellular responses over a single cycle, facilitating visualisation and deeper analysis of dynamic behaviours.

**3 Results and Discussion**

(simulation parameters) This chapter presents the results of GPU-based simulations for three cardiac cell models: ORd 2011, ORd 2017, and ToR-ORd. It analyses simulation accuracy, drug-induced changes, and computational performance. Two types of simulations were conducted: control (no drug) and drug-induced using bepridil at concentrations of 33 mMol, 66 mMol, and 132 mMol. Each simulation was run for 1000 pacing cycles, with each cycle lasting 1000 milliseconds.

(single-core simulation setup) Each simulation needs to simulate 8000 drug samples in multi-core situation. Single-core computational time also compared between CPU and GPU. Single-core performance focused on how each configuration (CPU and GPU) simulate only one drug sample. Both single-core and multi-core simulation uses the same parameters, drug, and concentration.

**Fig. 2.** Action Potential from GPU simulation in ORd 2011 model, compared to CPU simulation in non-drug and under-drug situation.

**3.1 Simulation Validation**

(method to validate simulation result) Simulation validation is a crucial step in ensuring the accuracy and reliability of GPU-based cardiac electrophysiology simulations. The results of the GPU simulations were validated by comparing them with CPU-based simulations using OpenCOR as the ground truth. Across all three cell models—ORd 2011, ORd 2017, and ToR-ORd—the validation process involved calculating the mean absolute error (MAE) between the GPU and CPU results and evaluating key electrophysiological biomarkers, including action potential duration (APD) and calcium transient properties.

(validation for ORd 2011) For the ORd 2011 model, the GPU simulation showed an MAE of 0.078 mV, demonstrating a high degree of accuracy. The Rush-Larsen method, used in this model for solving ordinary differential equations (ODEs), contributed to its computational stability and efficiency. The validation confirmed that the GPU accurately captured the physiological behaviours of the cardiac cells, including both control and drug-induced conditions, providing confidence in the simulation's robustness. Action potential result from both drug-free and under-drug simulation is visible in Figure 2.

(validation for ORd 2017) The ORd 2017 model achieved an exceptionally low MAE of 0.004 mV, reflecting near-perfect agreement with the CPU results. This model employed a forward Euler method for solving ODEs, which, while computationally more intensive than Rush-Larsen, delivered precise results. Validation under both no-drug and drug-induced conditions demonstrated the GPU’s capability to reproduce the intricate dynamics of the cardiac cells simulated in this model. Figure 3 shows action potential result from ORd 2017 model, both with and without drug simulation.

(validation for ToR-ORd) In the ToR-ORd model, the GPU simulation yielded an MAE of 0.023 mV, indicating strong alignment with the CPU reference. Despite the model's higher complexity and computational demands, the GPU efficiently handled both control and drug-induced scenarios. The simulation accurately replicated the cardiac cells' electrophysiological responses to bepridil at varying concentrations, further confirming the GPU's suitability for large-scale, high-fidelity simulations. ToR-ORd simulation result is shown in Figure 4. This figure shows action potential curve from drug-free, and drug-induced simulation.

**Fig. 4.** Action Potential from GPU simulation in ToR-ORd model, compared to CPU simulation in non-drug and under-drug situation.

**Fig. 3.** Action Potential from GPU simulation in ORd 2017 model, compared to CPU simulation in non-drug and under-drug situation.

(Validation Process Conclusion) Overall, the validation results for all three cell models underscore the accuracy and reliability of the GPU-based approach. The low MAE values across models confirm that the parallel computing implementation does not compromise the simulation's fidelity, making it a viable alternative to traditional CPU-based methods. These findings support the broader application of GPU-based simulations in cardiac electrophysiology and drug discovery research.

**3.2 Computation Time Performance**

**(Computational time comparison method)** The computational time performance of GPU-based simulations was compared against both single-core and multi-core CPU implementations for the three cardiac cell models: ORd 2011, ORd 2017, and ToR-ORd. This comparison highlights the efficiency gains achieved through CUDA-based parallel processing on GPUs.

(Computational time advantage for ORd 2011) For the ORd 2011 model, the GPU achieved significant time savings compared to its CPU counterparts. A single-core CPU required 57 seconds to complete the simulation for one sample, while a 10-core multi-core configuration took 45,600 seconds for 8,000 samples. In contrast, the GPU completed the same workload in just 928 seconds, representing a substantial speedup. This efficiency is attributed to the Rush-Larsen method employed in ORd 2011, which is well-suited for GPU parallelisation and reduces computational overhead.

**Table** 1. Simulation time for different cell models using CPU and GPU

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cell Model | Mean Absolute Error | Single-Core CPU Time (s) | Multi-Core CPU Time (s) | GPU Time (both Single and Multi-core) (s) |
| ORd 2011 | 0.078 | 57 | 45600 | **928** |
| ORd 2017 | 0.004 | 390 | 312000 | **40089** |
| ToR-ORd | 0.023 | 455 | 364000 | **38542** |
|  |  |  |  |  |

(Computational time advantage for ORd 2017) The ORd 2017 model, using a forward Euler ODE solver, was computationally more demanding. A single-core CPU required 390 seconds per sample, and the multi-core CPU setup took 312,000 seconds for 8,000 samples. Despite the increased complexity, the GPU outperformed the CPU significantly, completing the same task in 40,089 seconds. While the GPU’s advantage is slightly less pronounced for this model, it still demonstrated its capability to handle large-scale simulations more efficiently than traditional CPUs.

(Computational time advantage for ToR-ORd) The ToR-ORd model, being the most complex of the three, posed the greatest computational challenges. Single-core CPU simulations required 455 seconds per sample, and the multi-core setup took 364,000 seconds for 8,000 samples. In comparison, the GPU completed the same workload in 38,542 seconds, achieving a notable speedup. This performance demonstrates the scalability of GPU-based simulations for handling high-fidelity cardiac models with greater computational demands.

(Summary of Computational time advantages) Across all three cell models, the GPU consistently outperformed both single-core and multi-core CPU configurations, particularly as the sample size increased. The results underscore the GPU’s efficiency in large-scale simulations, making it a superior choice for computationally intensive applications. These findings highlight the GPU’s potential to accelerate cardiac electrophysiology research and reduce the time required for preclinical drug testing. Table 1 summaries all computational time, and GPU-based simulation compared with CPU.

**4. Conclusions, Limitations and Suggestions**

(Research conclusion and advantage) This research proven its ability to aim a more computationally efficient *in silico* cardiotoxicity prediction by leveraging CUDA-based parallel processing. CUDA enables this research to do massive parallelisation with up to 40.91 times faster simulation speed for 8000 drug samples, compared to CPU-based 10-core simulation. Validation results confirmed the accuracy of GPU simulation. Little to no difference were found in both GPU and the well-used CPU simulation results. This result highlights not only the GPU capability to produce more samples in shorter amount of time, but also it is similarly reliable to common CPU cardiotoxicity simulation.

(Research’s limitations) While this research demonstrates significant advancement in GPU-based parallel simulations *in silico* cardiotoxicity prediction, several limitations should be noted. First, this research restricts hardware use by requiring NVIDIA GPUs, as it relies on CUDA for its programming. This dependency makes the research incompatible with another brand’s GPU architecture. Another limitation is the reliance on simplified ODE solvers, such as the Rush-Larsen and forward Euler methods. Other methods should be heavily modified to be applied into this research. Furthermore, the fixed configurations for threads and blocks may not optimally utilise newer or varying GPU hardware, limiting future scalability.

(Research’s future expansions) This research focuses solely on drug-induced simulations using specific cell models and parameters, leaving the generalisation to other cell types or drugs unexplored. This point raises future suggestion to expand the research by incorporating another biological cell models and variables. More testing on diverse GPU hardware models would provide insights into performance variations across systems, ensuring broader applicability. Furthermore, assessing the economic viability of the GPU-based approach, including long-term operational costs and energy efficiency, could ensure its sustainability. Standardising protocols for simulation workflows would help maintain consistency and reproducibility, which are critical for scientific and industrial adoption.

**Acknowledgements** This research was partially supported by the Ministry of Food and Drug Safety (22213MFDS3922 and (24212MFDS266), National Research Foundation of Korea (NRF) under the Basic Science Research Program (2022R1A2C2006326), and Ministry of Science and ICT Korea (MSIT) under the Grand Information Technology Research Center support program (RS-2020-II201612) supervised by the Institute for Information and Communications Technology Planning and Evaluation (IITP).

**Declarations**

**Conflict of Interest:** The authors have no financial or any conflict of interest to declare in this research.

**References**

1. Jason Sanders and Edward Kandrot. 2010. CUDA by Example: An Introduction to General-Purpose GPU Programming (1st. ed.). Addison-Wesley Professional.

2. “What is OpenMP?” Accessed: Nov. 10, 2024. [Online]. Available: https://cvw.cac.cornell.edu/openmp/intro/what-is-openmp.

3. R. L. Graham, G. M. Shipman, B. W. Barrett, R. H. Castain, G. Bosilca and A. Lumsdaine, "Open MPI: A High-Performance, Heterogeneous MPI," 2006 IEEE International Conference on Cluster Computing, Barcelona, Spain, 2006, pp. 1-9, doi: 10.1109/CLUSTR.2006.311904.

4. A. Garny et al., “CellML and associated tools and techniques,” Sep. 13, 2008, Royal Society. doi: 10.1098/rsta.2008.0094.

5. M. Gómez, J. Carro, E. Pueyo, A. Pérez, A. Oliván, and V. Monasterio, “In Silico Modeling and Validation of the Effect of Calcium-Activated Potassium Current on Ventricular Repolarization in Failing Myocytes,” IEEE J Biomed Health Inform, pp. 1–9, 2024, doi: 10.1109/JBHI.2024.3495027.

6. C. M. Lloyd, J. R. Lawson, P. J. Hunter, and P. F. Nielsen, “The CellML Model Repository,” Bioinformatics, vol. 24, no. 18, pp. 2122–2123, 2008, doi: 10.1093/bioinformatics/btn390.

7. N. Le Novère et al., “BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems.,” Nucleic Acids Res, vol. 34, no. Database issue, 2006, doi: 10.1093/nar/gkj092.

8. M. Berghoff, J. Rosenbauer, F. Hoffmann, and A. Schug, “Cells in Silico-introducing a high-performance framework for large-scale tissue modeling,” BMC Bioinformatics, vol. 21, no. 1, Oct. 2020, doi: 10.1186/s12859-020-03728-7.

9. M. Martínez-del-Amor, I. Pérez-Hurtado, D. Orellana-Martín, and M. J. Pérez-Jiménez, “Adaptative parallel simulators for bioinspired computing models,” Future Generation Computer Systems, vol. 107, pp. 469–484, Jun. 2020, doi: 10.1016/j.future.2020.02.012.

10. S. McIntosh-Smith, J. Price, R. B. Sessions, and A. A. Ibarra, “High performance in silico virtual drug screening on many-core processors,” International Journal of High Performance Computing Applications, vol. 29, no. 2, pp. 119–134, May 2015, doi: 10.1177/1094342014528252.

11. P. Amar, M. Baillieul, D. Barth, B. LeCun, F. Quessette, and S. Vial, “Parallel Biological In Silico Simulation,” Nov. 2014, doi: 10.1007/978-3-319-09465-6\_40.

12. D. G. Whittaker, J. C. Hancox, and H. Zhang, “In Silico Assestment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome” Jan. 2019, doi: 10.3389/fphys.2018.01888.

13. T. O'Hara, L. Virág, A. Varró, and Y. Rudy, “Simulation of the Undiseased Human Cardiac Ventricular Action Potential: Model Formulation and Experimental Validation.” 2011, PLOS Computational Biology 7(5): e1002061. Available: https://doi.org/10.1371/journal.pcbi.1002061.

14. S. Dutta, K.C. Chang, K.A. Beattie, J. Sheng , P.N. Tran, W.W. Wu, M. Wu, D.G. Strauss, T. Colatsky, and Z. Li. "Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment." Front Physiol. Aug 2017 doi: 10.3389/fphys.2017.00616.

15. Tomek, Jakub et al. “Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block.” eLife vol. 8 e48890. Dec 2019, doi:10.7554/eLife.48890.

16. “Parallel Thread Execution ISA Version 8.5” Accessed: Nov. 24, 2024. [Online]. Available: https://docs.nvidia.com/cuda/parallel-thread-execution/index.html.

17. C., Yves, C. D. Lontsi, and C. Pierre. "Rush-Larsen time-stepping methods of high order for stiff problems in cardiac electrophysiology." 2017, arXiv preprint arXiv:1712.02260.

18. G.R. Mirams, Y. Cui, A. Sher, M. Fink, J. Cooper, B. M. Heath, et al. "Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk." 2011, Cardiovasc. Res. 91 (1), 53–61. doi:10.1093/cvr/cvr044.